研究单位：[1]BeiGene[2]Tongji Hospital of Tongji University Shanghai, Shanghai, China, 200092[3]West China Hospital ,Sichuan University Chengdu, Sichuan, China, 610041[4]Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Tianjin, Tianjin, China, 300020[5]The First Hospital of Zhejiang Province Hangzhou, Zhejiang, China, 310003[6]The first affiliated hospital of Wenzhou Medical University Wenzhou, Zhejiang, China, 325000[7]Beijing Friendship Hospital-Capital Medical University Beijing, China, 100050[8]Zhongshan hospital of Fudan University Shanghai, China, 200032[9]Tianjin Medical University Cancer Institute and Hospital Tianjin, China, 300060[10]Fakultni nemocnice Brno Brno, Jihomoravský Kraj, Czechia[11]Fakultni nemocnice Hradec Kralove Hradec Králové, Czechia[12]Fakultni nemocnice Olomouc Olomouc, Czechia[13]Fakultni nemocnice Ostrava Ostrava, Czechia[14]Hopital Prive Sevigne Cesson-Sévigné, France[15]Centre Hospitalier Departemental de Vendee La Roche-sur-Yon, France[16]Centre Hospitalier Le Mans Le Mans, France[17]Centre Hospitalier Lyon Sud Pierre Benite, France, 69495[18]CHRU de Poitiers La Miletrie Poitiers, France[19]Jiangsu Province Hospital Nanjing, Jiangsu, China, 210029[20]The affiliated Hospital of Xuzhou Medical university Xuzhou, Jiangsu, China, 221006[21]The First affiliated hospital of Nanchang University Nanchang, Jiangxi, China[22]The First Hospital of Jilin University Changchun, Jilin, China, 130021[23]Shengjing Hospital of China Medical University Shenyang, Liaoning, China, 110022
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
